DOI: 10.1038/nature09454
PLX4032 recently showed promising results in an early clinical trial of melanoma patients carrying a mutated version of the BRAF gene. Gideon Bollag and colleagues now explain the science behind the success story.
In particular, they note that sufficiently high levels of the drug, which works by blocking the activity of the oncogenic B-RAF protein, are needed to yield clinical effects, because the ERK signalling pathway, downstream of B-RAF, needs to be almost completely blocked.
The study demonstrates how the design of early clinical trials based on the biological mechanisms underlying tumour formation can speed the translation of anti-cancer drug from laboratory to clinic. And whilst the long-term effects of PLX4032 remain uncertain, it’s hoped that the small molecule inhibitor prove useful in combination with other targeted agents, immunotherapies or chemotherapies.
Author contact:
Gideon Bollag (Plexxikon Inc, Berkeley, CA, USA)
Tel: +1 510 647 4062
E-mail: [email protected]
PRESS CONTACTS…
From North America and Canada
Neda Afsarmanesh, Nature New York
Tel: +1 212 726 9231
E-mail: [email protected]
From Japan, Korea, China, Singapore and Taiwan
Mika Nakano, Nature Tokyo
Tel: +81 3 3267 8751
E-mail: [email protected]
From the UK
Ruth Francis, Nature London
Tel: +44 20 7843 4562
E-mail: [email protected]
About Nature Publishing Group (NPG):
Nature Publishing Group (NPG) is a publisher of high impact scientific and medical information in print and online. NPG publishes journals, online databases and services across the life, physical, chemical and applied sciences and clinical medicine.
Focusing on the needs of scientists, Nature (founded in 1869) is the leading weekly, international scientific journal. In addition, for this audience, NPG publishes a range of Nature research journals and Nature Reviews journals, plus a range of prestigious academic journals including society-owned publications. Online, nature.com provides over 5 million visitors per month with access to NPG publications and online databases and services, including Nature News and NatureJobs plus access to Nature Network and Nature Education’s Scitable.com.
Scientific American is at the heart of NPG’s newly-formed consumer media division, meeting the needs of the general public. Founded in 1845, Scientific American is the oldest continuously published magazine in the US and the leading authoritative publication for science in the general media. Together with scientificamerican.com and 15 local language editions around the world it reaches over 3 million consumers and scientists. Other titles include Scientific American Mind and Spektrum der Wissenschaft in Germany.
Throughout all its businesses NPG is dedicated to serving the scientific and medical communities and the wider scientifically interested general public. Part of Macmillan Publishers Limited, NPG is a global company with principal offices in London, New York and Tokyo, and offices in cities worldwide including Boston, Buenos Aires, Delhi, Hong Kong, Madrid, Barcelona, Munich, Heidelberg, Basingstoke, Melbourne, Paris, San Francisco, Seoul and Washington DC. For more information, please go to www.nature.com.
